Oscillations of cardiac wave length and proarrhythmia.
Drug-induced action potential duration (APD) prolongation was first proposed to be antiarrhythmic, but is now widely presumed to be torsadogenic. To elucidate this paradox, we tested the effect of APD upon liability for torsade de pointes. In addition, torsadogenicity is commonly associated with disturbances of repolarization, but at least in theory, it could also result from disturbances of conduction. These possibilities were tested in female rabbit hearts. Dofetilide, ATX II, and sodium channel blockers that did not prolong the action potential duration were used to modulate the APD and induce disturbances of conduction and disturbances of repolarization. Torsadogenicity could be induced by dofetilide and ATX II starting at normal APD (210 ms), reaching a peak incidence around a doubling of APD (400 to 450 ms), to then sharply decline with further APD prolongation, until torsade de pointes disappeared above 725 ms. Early afterdepolarizations (EAD) were regular triggers for torsade de pointes; while most of the EADs occurred in the plateau range, their incidence declined with repolarization but their potential for torsadogenicity increased. Sodium channel blockers that shorten the APD, even when devoid of hERG blocking properties, can yield torsade de pointes. Torsade de pointes can occur at normal, prolonged, and shortened APD, so that QT prolongation is an incomplete predictor of torsadogenicity. Torsade de pointes can result not only from disturbances of repolarization but also from disturbances of conduction.
Hondeghem
L M
LM
Department of Pharmacology, Catholic University, Leuven, Belgium. Luc.Hondeghem@screenQT.com
Dumotier
B
B
Traebert
M
M
D000200:Action Potentials / Q000187:drug effects / Q000502:physiology*; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology; D018929:Cell Culture Techniques; D002460:Cell Line; D005260:Female; D006329:Heart Conduction System / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D006352:Heart Ventricles / Q000378:metabolism; D006801:Humans; D018408:Patch-Clamp Techniques; D011817:Rabbits; D026941:Sodium Channel Blockers / Q000494:pharmacology; D015222:Sodium Channels / Q000378:metabolism; D016171:Torsades de Pointes / Q000139:chemically induced / Q000378:metabolism / Q000503:physiopathology*
D000889:Anti-Arrhythmia Agents; D026941:Sodium Channel Blockers; D015222:Sodium Channels
Arch Mal Coeur Vaiss. 1966 Feb;59(2):263-72
4956181
J Cardiovasc Electrophysiol. 1994 Aug;5(8):711-21
7528608
J Cardiovasc Electrophysiol. 1999 Feb;10(2):272-82
10090234
N Engl J Med. 2004 Mar 4;350(10):1013-22
14999113
J Cardiovasc Electrophysiol. 2006 Mar;17(3):337-40
16643415
J Cardiovasc Electrophysiol. 2001 May;12(5):538-45
11386514
Circ Res. 1998 Feb 23;82(3):386-95
9486667
Pacing Clin Electrophysiol. 2005 Mar;28(3):219-27
15733182
Circulation. 2001 Apr 17;103(15):2004-13
11306531
Am J Cardiol. 1987 Dec 1;60(16):1276-81
3318368
J Pharmacol Exp Ther. 2002 Oct;303(1):218-25
12235254
Am J Cardiol. 1993 Aug 26;72(6):53B-54B
8256757
Am J Cardiol. 1993 Aug 26;72(6):50B-52B
8256756
Circulation. 1990 Feb;81(2):686-90
2153477
Eur Heart J. 1991 Dec;12 Suppl F:4-9
1725155
Am J Physiol Heart Circ Physiol. 2003 Dec;285(6):H2722-33
12907420
J Cardiovasc Electrophysiol. 2003 Mar;14(3):287-94
12716112
Heart Rhythm. 2005 Jul;2(7):758-72
15992736
Biochim Biophys Acta. 1977 Nov 14;472(3-4):373-98
334262
J Physiol. 1984 Dec;357:127-49
6150992
Heart Rhythm. 2008 Aug;5(8):1210-2
18675236
Curr Opin Cardiol. 2007 Jan;22(1):39-43
17143043